Bioentrepreneur in 2006

Conflicts of interest in research can affect a company's ability to move a product through the approval process or attract investment. Avoid the pitfalls by taking pro-active steps to manage these risks.

The path may not always be clear, but government money to support biotech startups is there for the asking. You just need to know where to look.

The first few decisions bioentrepreneurs make when forming a company can come back to bite them later, but some careful planning can smooth the way for later success.

There's another kind of venture capitalist lurking in the corridors of capital.

As well as overcoming legal, cultural and linguistic barriers, European biotech companies must focus on building investor visibility, pharma collaborations and consolidation to boost their chances of successful exits.

The East provides increasing opportunities for biotech companies seeking to optimize product development and accelerate time to market. But any undertaking in China or India requires close scrutiny of the risks.

Getting a second date with a venture capitalist requires good planning and an ability to read between the lines.

An analysis of recent trends in licensing and financing transactions that affect early to mid-stage life science companies and their investors.

An analysis of recent trends in intellectual property that affect early- to mid-stage life sciences companies and their investors.

One year after its passage, California's embryonic stem cell research funding initiative remains a mixed blessing for biotech startups.

Are reverse mergers the answer to biotech's capital crunch? This IPO alternative, in which a viable company goes public through a defunct 'shell' company that no longer has operations, is becoming increasingly popular. But it pays to understand the downside, too.

Canadian citizens, the government and its entrepreneurs are all keen on biotech. Startup incentives, government supports and talent are not hard to find in Canada, but the message isn't getting out. Boosters think they know why and have a solution.

Specialized academic training, seminars and mentoring programs are slowly emerging to woo and equip female biotech entrepreneurs.

Nanobiotech entrepreneurs learned the hard way that there is such a thing as pushing so-called exotic or emerging technologies too hard with investors. Biotech entrepreneurs could learn a thing or two from their experience.

Will 2006 bring a new set of expectations about M&A among entrepreneurs?

China's biotech ambitions rest squarely upon the shoulders of Taiwan. Thus far, the tiny island is proving that it is up to the task.